The Pharmaceutical Company to Own
Companies such as Novartis (NYSE: NVS), Amgen (NASDAQ: AMGN), Teva Pharmaceuticals(NYSE: TEVA) and Sanofi (NYSE: SNY) are some of the biggest names in the biopharmaceutical industry. Each of these giants is worth more than $30B and have posted mild declines or mild gains in the one-year movement of their stock price; Amgen leads the pack with a 21.6% increase in its stock price from a year ago. Yet, there is one biopharmaceutical company that has seen its stock price increase 96% from a year ago; this company, with a $2.9B market cap, also posted growth that would put Novartis, Amgen, Teva, and Sanofi to shame.
Questcor Pharmaceuticals (NASDAQ: QCOR) is a biopharmaceutical company that sells two products: H.P. Acthar Gel, which is its flagship product, and Doral, which is used to treat insomnia. Questcor has been a favorite among mutual funds: its stock has experienced 8 consecutive quarters of increasing mutual fund ownership and it had a 4% YOY increase in mutual fund ownership for its first quarter of 2012. The appeal of Questcor's business is apparent upon closer analysis of the company, but some significant negatives also pop up. So is Questcor a good investment? Full article: here.